NasdaqGS:SRRKBiotechs
Scholar Rock (SRRK) Is Up 6.6% After Detailing 2026 Apitegromab Approval And Launch Strategy – What's Changed
Scholar Rock recently outlined its 2026 plans around potential U.S. and European approvals and commercial launch preparations for apitegromab in spinal muscular atrophy, alongside ongoing clinical trials and leadership changes to support a move toward commercialization.
An interesting angle is how Scholar Rock is extending apitegromab into younger SMA populations and facioscapulohumeral muscular dystrophy while scaling manufacturing and organizational capacity to support a broader...